Media headlines about Galena Biopharma (NASDAQ:GALE) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Galena Biopharma earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.4253165581117 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Separately, Raymond James Financial reiterated a “hold” rating on shares of Galena Biopharma in a research note on Monday, December 18th.

Galena Biopharma (GALE) opened at $0.28 on Tuesday. Galena Biopharma has a 12 month low of $0.26 and a 12 month high of $3.60. The company has a market capitalization of $12.58, a P/E ratio of -0.21 and a beta of 1.99.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Galena Biopharma (GALE) Stock Price” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at

Galena Biopharma Company Profile

Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.

Insider Buying and Selling by Quarter for Galena Biopharma (NASDAQ:GALE)

Receive News & Ratings for Galena Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma and related companies with's FREE daily email newsletter.